AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson

AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson

AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single global programme "ATLAS" containing all studies) Open-Access Register https://amr.theodi.org/6 Structure: author by eLibrary ESCMID © author by eLibrary ESCMID © What sort of data Pharmaceutical activities: - High-quality standardised data are collected? - Large Antimicrobial panel Lab Based - Many countries Surveillance - Stored in spreadsheets or (a WHO GLASS databases (integration a massive Category) author Reported challenge) by Culture-confirmed Lab tests for organisms Specimens obtained eLibrary People who seek healthcare People who become ill People infected with AMR bacteria ESCMID AMR surveillance© ‘pyramid’ What sort of data Programmes vary in: are collected? - Infection sites - Microorganisms and - Antimicrobials tested Issues can relateauthor to: Reported - Ability to identify Hospital- versus Community-by Acquired infections Culture-confirmed as inconsistently recorded or defined Lab tests for organisms - Denominator data: usually % susceptible organisms Specimens obtained BUT many variations: eLibrary e.g . limiting % per site or People who seek healthcare organism numbers People who become ill People infected with AMR bacteria ESCMID Resonates with SUSPIRE study: AMR surveillance© ‘pyramid’ CMI, 2018;24:105-9 Surveillance targets vary considerably between companies: in aggregate…… Microorganisms Antimicrobials Infection sites Acinetobacter baumannii author Burkholderia cepacia Amikacin Blood stream Citrobacter spp. Amoxicillin/clavulanateby Intra-abdominal Enterobacter spp. Ampicillin/sulbactam Skin Enterococcus spp. Azithromycin Soft tissue Escherichia coli Aztreonam/avibactam Respiratory tract Haemophilus influenzae Bedaquiline Urinary tract Klebsiella pneumoniae BenzylpenicillineLibrary Moraxella catarrhalis Biapenem Mycobacterium tuberculosis Capreomycin Pseudomonas aeruginosa Cefaclor/Cefazolin/Cefcapene Streptococcus pneumoniae Cefdinir/Cefditoren/Cefepime Serratia spp. Cefiderocol etc. Staphylococcus aureusESCMID N.B. not comprehensive list Staphylococcus spp.© and not all equally Stenotrophomonas maltophilia represented What is the scale of the data? author by No. of eLibrary ProgrammesESCMID in register have data on isolates from a total of © 93 countries and 85 antimicrobials. Sub Saharan Africa Poor Datasets: format, management, access Format Databases (7/12) - managed by specialised companies e.g. Micron, JMI, IHMA (via SLDN), LGC. author Spreadsheets (5/12) - managed internally by Access • Online password-protected to centre participants • Some datasets are public to some extent: ATLAS (Pfizer) - www.atlas-surveillance.comeLibrary (updated every 6-9 months) SMART (Merck) - www.globalsmartsite.com SOAR (GSK) - raw data are now available ScientificESCMID Publications - often include tabulated MIC distributions © Example of use MICs for cefuroxime against Streptococcus pneumoniae from China SOAR 114620 (GSK) • Downloaded author anonymized data from register for all isolates from India andby China N.B. this distribution ~2011-2014 was published as • Subsetted to S. Table 4 in the pneumoniae and cefuroxime in China associated GSK • Generated distribution SOAR publication: • Plotted Hu et al. (2016) JAC doi: 10.1093/jac/dkw065 % of isolates eLibrary Here Liam Shaw generated it from the raw data ESCMID © Second Workshop March 2018: Four Key Actions • Develop a public–private partnership between industry, public health organisations and other AMR initiatives for a more informative, coherent and openly accessible AMR data landscape author • Enable open innovation and catalyse databy sharing within the AMR community by encouraging reuse of shared industry AMR data with case studies (Wellcome to launch a Data Reuse prize ~Jan. 2019) • Facilitate development of commoneLibrary methodological and metadata standards and data governance frameworks so enabling the scientific and public health communities to utilise and compare data use with existing in-country datasets • Online portal ESCMIDlaunch managed and© governed by an independent party ` Collaboration Personnel (and Acknowledgements) Steering group 10 Company Nominated David Beardmore (ODI), Chair Lead Collaborators Pauline L’Henaff (ODI), Project Manager Seamus O’Brien (Pfizer now GARDP) Achaogen: Tiffany Keepers Didem Torumkuney (GSK) Allergan: author Ian Critchley Andrew Freeman (GSK) GSK: Didem Torumkuney Seamus O’Brien (Pfizer now GARDP) J&J: by Karen Grosser Najib Rehman (Pfizer now Merck: Mary Motyl, Kokoro & Farma Trust) Silas Holland Barry Cookson (Consultant: UCL) Novartis: Susana Goncalves Liam Shaw (Scientist: UCL) Pfizer: Michael Dowzicky Nandini Shetty (PHE) Roche: Claudia Zampaloni Allison Holt (Longitude 174) eLibrarySanofi: Christine Luxemburger Wellcome: Francesca Chiara, Shionogi: Yoshiri Yamano, Joanna Wiecek, Ghada Zoubiane Gareth Morgan &Tim Jinks One Data Institute technical team (IT)ESCMID Phil Lang, Olivier Thereaux & Myriam Wiesenfeld© .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    15 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us